Terns's stock soars as analysts cheer leukemia data — and predict more gains

Core Insights - Terns Pharmaceuticals Inc.'s stock increased by 14% following the release of positive data on a treatment for chronic myeloid leukemia [1] - Analysts from Mizuho, Graig Suvannavejh and Avantika Joshi, expressed optimism regarding the early-stage trial results of TERN-701 [1]